Zentiva sets out generics roll out targets to 2017

The Czech Republic’s biggest pharmaceutical company Zentiva says is looking to develop 11 new generic drugs for treatment of cardiovascular and respiratory illnesses throughout this year and going forward into 2017, the Pharma Letter's Czech Republic correspondent reports.

The company will also focus on the development of new generic drugs for cancer treatments, Prague-based spokesman for Zentiva, Filip Hruby, added. No further details of the drugs or their expected roll out dates could be given, he said.

Zentiva is the main European branded generics drug company of France’s Sanofi (Euronext: SAN). Sanofi chief executive Olivier Brandicourt raised speculation that it might be seeking to offload Zentiva when he said in the fall that tough competition in the generics sector meant reflection about the future of the generics business within the group was required.